How it began
The TxMiller Foundation was established in 2024 by GenDx co-founders Erik Rozemuller PhD, and Wietse Mulder PhD. The Foundation is partially funded through the sale of GenDx in October 2022, along with donations from individual donors and private organizations.
Since we understand the impact a donor can have on a patient’s life, we are committed to advancing the field of Life Sciences, with a special focus on transplantation. Our mission is to improve the quality of life and survival of transplant patients.
The name TxMiller reflects both our mission and our heritage:
‘Tx’ refers to the field of transplantation.
‘Miller’ combines both founders’ last names and honors their Dutch heritage, the country known for its renowned windmills.
Who we are
Wietse Mulder PhD
Founder
Read more….
Erik Rozemuller PhD
Founder
Read more….
TxMiller Foundation
Our Team
Read more…
General Information
TxMiller Foundation
Karpervijver 17
3703 CJ Zeist
The Netherlands
Chamber of Commerce: 95437401
RSIN: 867130386
Bank account: NL88 ABNA 0140 3808 68
BIC: ABNANL2A
Governance & Policy
The board consists of:
– Em. Prof. Dr. Ronald Bontrop, chair
– Dr. Wietse Mulder, treasurer
– Dr. Erik Rozemuller, board member
The board members perform their duties on a voluntary basis and receive no compensation. Our plans are summarized in our policy plan (available in Dutch). The operating account is published within three months after the end of the financial year.
TxMiller® is a registered brand in the Benelux. Markedly sponsored this registration.
Wietse Mulder
With several decades of experience in the life sciences, Wietse Mulder is an experienced entrepreneur, investor, and board member known for his deep commitment to advancing molecular diagnostics and immunotherapy. Throughout his career, he has established, led, and successfully exited multiple companies, while actively supporting and advising emerging ventures shaping the future of biotechnology.
Wietse’s leadership track record spans several impactful roles. He served as CEO of KimerDx BV from October 2013 to March 2020, and for about twenty years he led GenDx—holding the position of CEO at GenDx from January 2004 to July 2023, and at GenDx Products Inc from August 2007 to July 2023. Under his guidance, these organizations grew into internationally respected players in the fields of transplantation diagnostics and sequencing technologies.
Driven by scientific curiosity and mission-driven entrepreneurial vision, Wietse continues to contribute his expertise to companies and initiatives that push the boundaries of modern life sciences.
Erik Rozemuller
Erik Rozemuller brings extensive expertise in bioinformatics, with a strong focus on software development related to genetic polymorphisms and mutations. His career began at the UMC Utrecht, where he worked as a scientist from August 1982 until December 2008, contributing to pioneering research in medical genetics.
In January 2005, Erik joined GenDx as a senior scientist, a role he held until July 2023. During these years, he played a key part in advancing innovative tools and methodologies for HLA typing and molecular diagnostics, helping to strengthen GenDx’s reputation as a leading company in the field. He has played a central role in developing various clinically used software applications, including SBTengine® and NGSengine®.
Today, Erik applies his knowledge and experience as a board member of the TxMiller Foundation. Outside of his professional commitments, he enjoys spending quality time with his children and grandchildren, embracing a fulfilling and active life beyond science.
Our Team
Our team, from left to right:
Wietse Mulder PhD
Jeanine Verbeek
Daniëlle Baalman
Roelien Brommersma
Erik Rozemuller PhD